Publication: Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Open/View Files
Date
2008
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
New England Journal of Medicine (NEJM/MMS)
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Rothenberg, Marc E., Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter F. Weller, Hans-Uwe Simon, Lawrence B. Schwartz, et al. 2008. “Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab.” New England Journal of Medicine 358 (12) (March 20): 1215–1228. doi:10.1056/nejmoa070812.
Research Data
Abstract
The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service